Lausanne, Switzerland, 13th September 2025. Rheon Medical SA announced today that it has received CE Mark certification under the European Medical Device Regulation (MDR 2017/745) for its innovative glaucoma drainage devices, the eyeWatch system and eyePlate implants.
This new approval also covers two new additions to the product portfolio: the eyePlate-200s and eyePlate-300s. These new “S” models feature a smaller tube size, offering surgeons enhanced versatility and expanding treatment options for patients with glaucoma.
The MDR certification marks an important milestone for Rheon Medical, reinforcing the company’s commitment to delivering innovative, safe, and effective treatment solutions for glaucoma patients across Europe.
“MDR certification for all our products represents a major milestone,” said Nikos Stergiopulos, CEO of Rheon Medical. “The introduction of the new eyePlate-S models responds boldly to surgeons’ demand for a simpler, faster, safer and more efficacious treatment.”
“After more than 100 eyePlate-200s cases, I am very impressed with its safety and outcomes. Its flexible plate is easy to position, minimizing diplopia risk, and the design lets me gauge aqueous flow intraoperatively. The small-diameter tube with ripcord control and the quick, under-15-minute implantation make it the fastest glaucoma drainage device I use” said Prof. Tarek Shaarawy.
In parallel, Rheon Medical has successfully renewed its ISO 13485 certification, now valid until 2028, further demonstrating the company’s commitment to maintaining its high standards of quality and regulatory compliance.
For more information, please contact:
Rheon Medical SA
Contact e-mail: [email protected]
Website : www.rheonmedical.com